Aneurysm Treatment Articles & Analysis
6 news found
Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. The IDE approval follows the receipt of Breakthrough Device Designation from the FDA in February 2021. ...
The designation expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly. Indicated for the treatment of intracranial aneurysms, the Contour Neurovascular System™, composed of fine mesh braid, represents a unique intrasaccular advancement in the market, as it targets ...
Flow diverters are intended to divert blood flow away from an aneurysm, allowing the aneurysm to heal and reducing the risk of aneurysm rupture. ...
Cerus Endovascular Ltd., a privately held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System is a unique, fine mesh braid ...
Cerus Endovascular Ltd., a privatelyheld, commercial stage medical device company, today announced that it has received CE Mark approval for its Neqstent Coil Assisted Flow Diverter device, designed to treat intracranial aneurysms. Neqstent is designed to treat a range of aneurysm morphologies including wide-necked bifurcation and bifurcation ...
Completion of the Series B financing will allow the company to execute on its go-to-market strategy and to complete the planned expansion of its product portfolio, which will include a smaller delivery platform for its recently CE Marked lead product, the Contour Neurovascular System, for the treatment of intracranial aneurysms. The company’s second ...